Baseline characteristics of allogeneic HSCT cohort according to sirolimus use for GVHD prophylaxis (DFCI/BWH April 2000-June 2004)
| Characteristic . | Sirolimus GVHD prophylaxis (%)* . | Nonsirolimus GVHD prophylaxis (%) . | P . |
|---|---|---|---|
| No. of patients | 252 | 354 | — |
| CMV serostatus | .087 | ||
| CMV D-/R- | 90 (35.7) | 156 (44.1) | |
| CMV D+/R- | 48 (19.1) | 67 (18.9) | |
| CMV D+/R+ | 56 (22.2) | 54 (15.2) | |
| CMV D-/R+ | 58 (23.0) | 77 (21.8) | |
| Median age, years (IQR, range) | 45 (34-53, 18-69) | 45 (36-53, 18-70) | .68 |
| Male sex | 156 (61.9) | 201 (56.8) | .21 |
| Race | .05 | ||
| White | 241 (95.6) | 323 (91.2) | |
| Nonwhite | 11 (4.4) | 31 (8.8) | |
| Primary disease | .03 | ||
| ALL | 19 (7.5) | 39 (11.0) | |
| AML | 61 (24.2) | 116 (32.8) | |
| CLL | 20 (7.9) | 30 (8.5) | |
| CML | 45 (17.9) | 45 (12.7) | |
| MDS | 34 (13.5) | 52 (14.7) | |
| NHL | 45 (17.9) | 39 (11.0) | |
| Other | 28 (11.1) | 33 (9.3) | |
| Conditioning | .67 | ||
| Myeloablative | 156 (61.7) | 212 (59.9) | |
| Reduced-intensity | 96 (38.1) | 142 (40.1) | |
| Stem cell source | .013 | ||
| Peripheral blood | 187 (74.2) | 228 (64.4) | |
| Bone marrow | 65 (25.8) | 126 (35.6) | |
| HLA match | .29 | ||
| Matched | 221 (87.7) | 320 (90.4) | |
| Mismatched | 31 (12.3) | 34 (9.6) | |
| Donor relatedness | .001 | ||
| Related | 100 (39.7) | 191 (54.0) | |
| Unrelated | 152 (60.3) | 163 (46.0) | |
| BMT disease risk group | .72 | ||
| Low | 74 (29.4) | 103 (29.1) | |
| Intermediate | 138 (54.7) | 186 (52.5) | |
| High | 40 (15.9) | 65 (18.4) | |
| Acute GVHD | .01 | ||
| None or grade I | 185 (73.4) | 225 (63.6) | |
| Grades II-IV | 67 (26.6) | 129 (36.4) | |
| GVHD prophylaxis regimen | < .001 | ||
| Prednisone | 0 | 110 (31.1) | |
| Cyclosporine | 0 | 127 (35.9) | |
| Tacrolimus | 252 (100) | 199 (56.2) | |
| Methotrexate | 188 (74.6) | 194 (54.8) | |
| Mycophenolate mofetil | 5 (2.0) | 43 (12.1) | |
| T-cell depletion | 0 | 75 (21.2) | |
| Transplantation period | < .001 | ||
| 4/2000-6/2001 | 38 (15.1) | 119 (33.6) | |
| 7/2001-6/2002 | 18 (7.1) | 126 (35.6) | |
| 7/2002-6/2003 | 84 (33.3) | 66 (18.6) | |
| 7/2003-6/2004 | 112 (44.4) | 43 (12.2) |
| Characteristic . | Sirolimus GVHD prophylaxis (%)* . | Nonsirolimus GVHD prophylaxis (%) . | P . |
|---|---|---|---|
| No. of patients | 252 | 354 | — |
| CMV serostatus | .087 | ||
| CMV D-/R- | 90 (35.7) | 156 (44.1) | |
| CMV D+/R- | 48 (19.1) | 67 (18.9) | |
| CMV D+/R+ | 56 (22.2) | 54 (15.2) | |
| CMV D-/R+ | 58 (23.0) | 77 (21.8) | |
| Median age, years (IQR, range) | 45 (34-53, 18-69) | 45 (36-53, 18-70) | .68 |
| Male sex | 156 (61.9) | 201 (56.8) | .21 |
| Race | .05 | ||
| White | 241 (95.6) | 323 (91.2) | |
| Nonwhite | 11 (4.4) | 31 (8.8) | |
| Primary disease | .03 | ||
| ALL | 19 (7.5) | 39 (11.0) | |
| AML | 61 (24.2) | 116 (32.8) | |
| CLL | 20 (7.9) | 30 (8.5) | |
| CML | 45 (17.9) | 45 (12.7) | |
| MDS | 34 (13.5) | 52 (14.7) | |
| NHL | 45 (17.9) | 39 (11.0) | |
| Other | 28 (11.1) | 33 (9.3) | |
| Conditioning | .67 | ||
| Myeloablative | 156 (61.7) | 212 (59.9) | |
| Reduced-intensity | 96 (38.1) | 142 (40.1) | |
| Stem cell source | .013 | ||
| Peripheral blood | 187 (74.2) | 228 (64.4) | |
| Bone marrow | 65 (25.8) | 126 (35.6) | |
| HLA match | .29 | ||
| Matched | 221 (87.7) | 320 (90.4) | |
| Mismatched | 31 (12.3) | 34 (9.6) | |
| Donor relatedness | .001 | ||
| Related | 100 (39.7) | 191 (54.0) | |
| Unrelated | 152 (60.3) | 163 (46.0) | |
| BMT disease risk group | .72 | ||
| Low | 74 (29.4) | 103 (29.1) | |
| Intermediate | 138 (54.7) | 186 (52.5) | |
| High | 40 (15.9) | 65 (18.4) | |
| Acute GVHD | .01 | ||
| None or grade I | 185 (73.4) | 225 (63.6) | |
| Grades II-IV | 67 (26.6) | 129 (36.4) | |
| GVHD prophylaxis regimen | < .001 | ||
| Prednisone | 0 | 110 (31.1) | |
| Cyclosporine | 0 | 127 (35.9) | |
| Tacrolimus | 252 (100) | 199 (56.2) | |
| Methotrexate | 188 (74.6) | 194 (54.8) | |
| Mycophenolate mofetil | 5 (2.0) | 43 (12.1) | |
| T-cell depletion | 0 | 75 (21.2) | |
| Transplantation period | < .001 | ||
| 4/2000-6/2001 | 38 (15.1) | 119 (33.6) | |
| 7/2001-6/2002 | 18 (7.1) | 126 (35.6) | |
| 7/2002-6/2003 | 84 (33.3) | 66 (18.6) | |
| 7/2003-6/2004 | 112 (44.4) | 43 (12.2) |
— indicates not applicable.
Percentages in parenthesis refer to the total of patients in each column. Total numbers are the same as in Table 1.